While modern incretin therapies are highly effective, adverse gastrointestinal effects and inflexible dosing regimens remain major barriers to long-term adherence. This project addresses these challenges by developing a dose-modifying biodegradable implant that enables gradual, controllable drug release over extended periods. Using 3D printing for rapid prototyping, the research will investigate how implant geometry, material selection, and formulation influence release profiles, with the goal of producing functional prototypes capable of flexible dosing strategies.

The student will work within Queen’s University Belfast research teams and collaborate closely with an industrial sponsor, gaining exposure to both academic and industry-led drug development. Training will encompass a wide range of advanced analytical and characterisation techniques, including 3D printing, microscopy, thermal analysis, spectroscopy, rheology, mechanical testing, and in vitro release studies. Alongside technical development, the project offers strong opportunities for professional growth through conference attendance, industry engagement, public outreach, and dissemination of findings via presentations and peer-reviewed publications.

APPLICATION DEADLINE: 23rd February 2026

ANTICIPATED START DATE: 1st May 2026

READ MORE AND APPLY BY CLICKING HERE